WallStSmart

Aurora Cannabis Inc (ACB)vsViatris Inc (VTRS)

VS

Smart Verdict

WallStSmart Research — data-driven comparison

Viatris Inc generates 4592% more annual revenue ($14.74B vs $314.07M). VTRS leads profitability with a -2.8% profit margin vs -38.3%. VTRS earns a higher WallStSmart Score of 48/100 (D+).

ACB

Avoid

29

out of 100

Grade: F

Growth: 4.0Profit: 2.0Value: 5.0Quality: 6.5
Piotroski: 3/9Altman Z: -10.67

VTRS

Hold

48

out of 100

Grade: D+

Growth: 2.7Profit: 3.5Value: 4.3Quality: 5.0
Piotroski: 4/9Altman Z: 0.55
IV

Intrinsic Value Comparison

Multi-model valuation · Graham Formula

Intrinsic value data unavailable for ACB.

VTRSSignificantly Overvalued (-84.5%)

Margin of Safety

-84.5%

Fair Value

$8.74

Current Price

$17.18

$8.44 premium

UndervaluedFair: $8.74Overvalued

Key Strengths & Concerns

Side-by-side fundamental analysis

Key Strengths

ACB2 strengths · Avg: 10.0/10
Price/BookValuation
0.7x10/10

Reasonable price relative to book value

Debt/EquityHealth
0.0410/10

Conservative balance sheet, low leverage

VTRS1 strengths · Avg: 10.0/10
Price/BookValuation
1.4x10/10

Reasonable price relative to book value

Areas to Watch

ACB4 concerns · Avg: 2.5/10
Market CapQuality
$236.15M3/10

Smaller company, higher risk/reward

Piotroski F-ScoreQuality
3/93/10

Weak financial health signals

Return on EquityProfitability
-7.9%2/10

ROE of -7.9% — below average capital efficiency

Revenue GrowthGrowth
-8.8%2/10

Revenue declined 8.8%

VTRS4 concerns · Avg: 2.5/10
Revenue GrowthGrowth
4.9%4/10

4.9% revenue growth

Return on EquityProfitability
-2.9%2/10

ROE of -2.9% — below average capital efficiency

EPS GrowthGrowth
-70.6%2/10

Earnings declined 70.6%

Altman Z-ScoreHealth
0.552/10

Distress zone — elevated risk

Comparative Analysis Report

WallStSmart Research

Bull Case : ACB

The strongest argument for ACB centers on Price/Book, Debt/Equity.

Bull Case : VTRS

The strongest argument for VTRS centers on Price/Book. PEG of 1.05 suggests the stock is reasonably priced for its growth.

Bear Case : ACB

The primary concerns for ACB are Market Cap, Piotroski F-Score, Return on Equity.

Bear Case : VTRS

The primary concerns for VTRS are Revenue Growth, Return on Equity, EPS Growth.

Key Dynamics to Monitor

ACB carries more volatility with a beta of 1.45 — expect wider price swings.

VTRS is growing revenue faster at 4.9% — sustainability is the question.

VTRS generates stronger free cash flow (329M), providing more financial flexibility.

Monitor DRUG MANUFACTURERS - SPECIALTY & GENERIC industry trends, competitive dynamics, and regulatory changes.

Bottom Line

VTRS scores higher overall (48/100 vs 29/100). Both earn "Hold" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.

This analysis is generated from publicly available financial data. Not financial advice.

Aurora Cannabis Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Aurora Cannabis Inc. produces and distributes medical cannabis products globally. The company is headquartered in Edmonton, Canada.

Viatris Inc

HEALTHCARE · DRUG MANUFACTURERS - SPECIALTY & GENERIC · USA

Viatris Inc. is an American global healthcare company headquartered in Canonsburg, Pennsylvania.

Visit Website →

Want to dig deeper into these stocks?